Embody vs MEDVi: Which GLP-1 Program Is Better in 2026?

The 30-second verdict

The whole decision in one table. Everything under it is proof.

Prices are provider-stated and captured July 16, 2026. Confirm your exact plan, dose, and total at checkout before paying.

The one honest catch we have to tell you first

We're recommending Embody for most price-first shoppers. So before we say another good thing about it, you deserve its biggest weak spot.

If a strong track record matters to you more than the lowest price, MEDVi is the better choice — skip to the decision section or check MEDVi's current options. But because Embody's price is genuinely lower and locked, and its plan is simple, it's still the better value for a cash-pay shopper who cares most about cost and is willing to check their order carefully.

Embody vs MEDVi at a glance

The bottom line: Embody wins on price — a flat $79/month for compounded semaglutide, versus MEDVi's $179 first month and about $299 for refills. MEDVi wins on tablet options and a much larger, higher-rated review base. Both sell compounded medicine that is not FDA-approved, and MEDVi carries a 2026 FDA warning it publicly disputes.

We label how sure we are of each fact: Verified = we saw it in an official source. Provider-stated = the company's own claim. Calculated = our math. Verify at checkout = can change, confirm yourself.

Two things worth flagging: notice the pharmacy overlap — both companies publicly list RedRock Pharmacy and Triad Rx. Neither one makes the medicine itself; outside pharmacies do. Second, the FDA warning row is the one people react to hardest — it's more complicated than a headline. See the full breakdown below.

Should you choose Embody or MEDVi?

The bottom line: Pick Embody if your main goal is the lowest cash price and you're fine with compounded medicine once a clinician approves it. Pick MEDVi if you want a tablet, a bigger review history, or bundled coaching, and you're okay paying more. Pick neither if you need an FDA-approved brand, insurance help, or in-person care.

How much do Embody and MEDVi really cost?

The bottom line: Embody is far cheaper for most people — a flat $79/month for compounded semaglutide versus MEDVi's $179 first month and about $299 for refills. Over a year on a month-to-month plan, that's roughly $948 with Embody versus $3,468 with MEDVi. Prepay a 12-month Embody plan and it drops to about $828.

What Embody costs

Embody's current active plan (its terms were last updated in 2026 and list this pricing) is straightforward:

• Semaglutide: $79/month, flat. No increase as your dose climbs.
• Tirzepatide: $129/month, flat.
• Prepay and save: semaglutide drops to about $76 (3-month), $73 (6-month), and $69 (12-month) per month. Full commitments — Embody generally won't refund unused months.
• Needle-free gum: compounded semaglutide gum at $229/month.

What MEDVi costs

MEDVi lists $179 for your first month of compounded semaglutide, then about $299/month for refills. Tirzepatide starts higher (around $349). Tablets start around $249 (semaglutide) and $279 (tirzepatide). MEDVi's site uses live pricing that can shift, so the checkout screen is the number that counts.

The real 12-month picture

Same medicine (compounded semaglutide), month-to-month, prices captured July 16, 2026.

And if you're willing to prepay for the lowest rate:

What medications and formats does each offer?

The bottom line: Embody focuses on weekly compounded semaglutide and tirzepatide injections, plus a compounded semaglutide gum for people who won't do needles. MEDVi offers compounded injections and dissolvable tablets, plus a separate, pricier path to brand-name Wegovy and Zepbound. Compounded means a pharmacy makes it to a prescription — it is not FDA-approved, and it is not a generic version of Wegovy or Ozempic.

Embody's options

Embody is injection-first: a weekly shot of compounded semaglutide or tirzepatide, if a clinician approves you.

Won't do needles? Embody currently sells a compounded semaglutide gum ($229/month, listed in stock). It's a real, current needle-free option — just note it's a compounded formulation, not the FDA-approved Wegovy tablet or any other FDA-approved oral GLP-1, and it may not be available in every state. Confirm availability in your state before you count on it.

MEDVi's options

MEDVi offers weekly injections and daily dissolvable tablets for both semaglutide and tirzepatide. The tablet is the main reason a needle-averse shopper picks MEDVi. Same caution applies: MEDVi's tablet is a compounded formulation, not the FDA-approved Wegovy tablet, and hasn't gone through FDA review for safety, dosing, or how well it's absorbed. Ask MEDVi's clinician what to expect.

MEDVi also runs a separate brand-name path for FDA-approved Wegovy and Zepbound, priced differently (a membership plus the medication cost). Don't mix that up with the $179 compounded plan — the compounded plan does not include an FDA-approved drug.

Are Embody and MEDVi legit, and who actually makes the medicine?

The bottom line: Both are real, identifiable telehealth companies with named legal entities, licensed clinicians, and disclosed pharmacy partners. Neither one is the pharmacy — an outside compounding pharmacy makes and ships your medicine. The smartest way to protect yourself is to verify your prescriber, your assigned pharmacy, and your label — not to trust a logo.

A fact that surprises people: the telehealth brand is usually not the compounder. They connect you to a clinician and a pharmacy. Part of MEDVi's FDA warning was about labels that suggested MEDVi made the drug when it didn't. So verifying the actual pharmacy isn't paranoia — it's exactly what the FDA tells patients to do.

Who runs each, and which pharmacies they use

• Embody is operated by Modern Metabolic Medicine, Inc. (Wilmington, DE). Its care runs through an affiliated network of licensed clinicians (pages reference OpenLoop Health and CareGLP Affiliated P.C.s). Disclosed pharmacies: RedRock, Health Warehouse, Precision Compounding, and Triad Rx.
• MEDVi is operated by MEDVi, LLC (Newark, DE), also using OpenLoop-affiliated clinicians. Disclosed pharmacies: Triad Rx, RedRock, and Beaker Pharmacy & Compounding.

Both are LegitScript-certified. Notice the overlap: RedRock and Triad Rx appear on both lists. That's a disclosed partner network, though — not a promise that a specific pharmacy will fill your prescription.

How to check your medicine before you use it

1. Ask for the pharmacy's name before your order ships.
2. Look it up on your state's Board of Pharmacy website.
3. Confirm the license is active and that it can ship to your state.
4. Read the label when it arrives.
5. Call the pharmacy with any dosing or storage questions.

Check for: your name, the prescriber, the dispensing pharmacy, the medication and formulation, the strength (concentration), directions, a beyond-use or expiration date, storage instructions, and pharmacy contact info. If the medicine looks different than the website photo, arrives warm, or the label is sloppy or missing details, don't use it — call first. (The FDA specifically warns about warm-arriving injectables and fake pharmacy names on labels.)

For more on Embody's pharmacy partners, see our pharmacy verification guide.

What does MEDVi's FDA warning letter mean?

The bottom line: On February 20, 2026, the FDA issued and published a warning letter addressed to MEDVi, LLC over false or misleading marketing — specifically, product labels that implied MEDVi was the compounder, and "same active ingredient as Wegovy and Ozempic" claims the FDA said falsely imply FDA approval. MEDVi publicly disputes it, saying the cited site belonged to an affiliate. The letter did not report a recall, contamination, a shutdown, or a finding that any patient was harmed.

What the FDA actually objected to

The FDA reviewed website content (at the address medvi.io) in December 2025 and flagged two things:

• The labels showed "MEDVi" in a way that implied MEDVi made the compounded drugs — but MEDVi is not the compounder. The FDA calls that "misbranded" (the labeling is false or misleading).
• The site claimed "same active ingredient as Wegovy® and Ozempic®" (and the same for Mounjaro/Zepbound). The FDA said this implies the products were FDA-approved or reviewed for safety and effectiveness when they were not.

The FDA asked for a written response within 15 working days and for the claims to be fixed or removed.

MEDVi's response

In an April 8, 2026 public statement, MEDVi said the FDA letter referenced the URL medvi.io — which it describes as an affiliate marketing agency's site with outdated copy — and not MEDVi's own address, medvi.org. MEDVi said it required the affiliate to remove the material, and stated plainly: "MEDVi has never received a letter from the FDA." It also said it had cracked down on ads that appeared to feature AI-generated "doctors."

Here's the tension you should weigh: the FDA's published letter is addressed to "MEDVi, LLC dba MEDVi" at MEDVi's own Newark, Delaware corporate address — the same address on MEDVi's website. So MEDVi disputes ownership of the cited site, while the FDA document names MEDVi directly. The public record doesn't fully resolve that disagreement. We're not picking a winner here; we're showing you both so you can decide how much it matters to you.

What the warning did not establish

• It did not say any MEDVi patient got an unsafe product.
• It did not say MEDVi's partner pharmacies were unlicensed.
• It did not shut MEDVi down.
• It did not say all compounded semaglutide is illegal.
• It did not mean the FDA tested the medicine or found contamination.

As of our July 16, 2026 check, we did not find a posted FDA "close-out" letter (the notice the FDA issues when it considers a matter resolved). That absence doesn't prove anything either way — regulatory status can keep evolving through communications that aren't all public.

Bottom line: if MEDVi's tablets or review history make it your pick, this is a reason to read the current site carefully and ask questions — not automatically a dealbreaker. If it is a dealbreaker for you, that's a reasonable line to draw, and Embody or an FDA-approved route fits better.

Are these medications FDA-approved?

The bottom line: No. The compounded medicines in both cash-pay programs are not FDA-approved, which means the FDA does not check them for safety, effectiveness, or quality before they're sold. A compounded drug is not an FDA-approved generic of Wegovy, Ozempic, Mounjaro, or Zepbound. If having an FDA-approved product matters to you, choose a brand-name route.

Words you should never see used to sell it

The FDA has warned telehealth companies about exactly this language. Be skeptical of any site that calls a compounded drug:

• "Generic Wegovy" / "Generic Ozempic" / "Generic Zepbound"
• "Same active ingredient" as a brand drug
• "FDA-approved" or "FDA-approved pharmacy"
• "Just as safe," "just as effective," or "clinically proven equivalent"

That's not a technicality — the "same active ingredient" claim is the specific thing that drew the MEDVi warning. We won't use that language, and you shouldn't trust a page that does.

Can pharmacies still compound semaglutide or tirzepatide now that the shortages are over?

Short answer: sometimes, but the window has narrowed a lot.

• The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025. The grace periods for compounding ended in 2025.
• Once a drug is off the shortage list, a 503A pharmacy generally can't routinely make something that's "essentially a copy" of an available FDA-approved drug — unless a prescriber documents a real, specific reason for an individual patient.
• 503B outsourcing facilities generally can't compound from bulk unless the drug is on the "503B bulks list." Semaglutide and tirzepatide aren't on it.
• On April 30, 2026, the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, saying it found no clinical need for outsourcing facilities to make them from bulk. The FDA took public comments through June 29, 2026, before a final decision. This is a proposal, not a finished ban.

What do real customers say about Embody and MEDVi?

The bottom line: MEDVi has the stronger public review record — 4.4 out of 5 across more than 14,000 Trustpilot reviews, versus Embody's 3.6 out of 5 across roughly 2,600 reviews (about 1 in 4 one-star). Reviews are useful for spotting patterns in shipping, billing, and support. They are not proof that any medication is safe or effective for you.

Embody's Trustpilot profile notes that one or more company profiles were merged, which affects how you read the count and history.

We have no relationship with individual reviewers. Ratings change — read a current page yourself before you rely on any single one. Both companies' Trustpilot profiles are public. For more, see our full Embody review and MEDVi review.

Which is easier to cancel or get a refund from?

The bottom line: MEDVi's cancellation deadline is later and more forgiving — at least 72 hours before your next billing date — while Embody asks for at least 5 days before your period ends. Neither company refunds medicine once it's been made for you. The safe move with either is to cancel early, in writing, and keep the confirmation.

This is where people lose money. Read it twice.

The "safest-practice" row is our advice, not the contract — give yourself a buffer so a slow email doesn't cost you a month. Note Embody's refund cutoff isn't just "after it ships" — once your medicine is prescribed or compounded, it's generally nonrefundable.

A cancellation message you can copy

Save all of it: your request, the timestamp, their reply, your account status, and your next-billing screen. Screenshots are your best evidence if a billing dispute ever comes up.

For a step-by-step cancellation guide with an interactive date calculator, see How to cancel Embody GLP-1.

Is Embody or MEDVi available in my state?

The bottom line: Don't assume every medication and format is available everywhere. A clinician's license, a pharmacy's shipping rules, and your state's telehealth laws can all change what you're offered. Confirm your state, your medication, and your assigned pharmacy before you pay.

Both companies say services are limited to certain states. Rather than trust a stale "available in all 50 states" claim, ask support these five questions before paying:

1. Do you prescribe this exact medication and form in my state right now?
2. Do I need a live video visit?
3. Which pharmacy will fill it?
4. Is that pharmacy licensed to ship to me?
5. What's the full amount due before anything ships?

If you can't get clear answers, that's your answer.

How we researched this comparison

The bottom line: This is a document-based comparison, not a personal treatment diary. We read each company's live pricing, terms, and policies, checked FDA records, and pulled review data — then labeled every fact by how sure we are. We did not personally enroll in either program.

We built this because several existing "Embody vs MEDVi" pages still show Embody's old pricing and skip the FDA history. You can read our full Embody review and MEDVi review for the deep dives on each.

Final verdict: Embody or MEDVi?

The bottom line: Embody is the better pick for the typical price-first, cash-pay shopper — its flat $79/month beats MEDVi's $179-then-$299 by a wide margin, as long as your price checks out at checkout. MEDVi is the better pick if you want a tablet, a bigger review history, or coaching and you're okay paying more, and after you've weighed its FDA warning and response. Neither is right if you need an FDA-approved brand or insurance support.

Frequently asked questions